(2018). Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR? receptor. Journal of Neuroinflammation, 19 - ?. https://doi.org/10.1186/s12974-018-1060-5